当前位置: 首页 >> 检索结果
5050. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
作者: Timothy Craig.;Markus Magerl.;Donald S Levy.;Avner Reshef.;William R Lumry.;Inmaculada Martinez-Saguer.;Joshua S Jacobs.;William H Yang.;Bruce Ritchie.;Emel Aygören-Pürsün.;Paul K Keith.;Paula Busse.;Henrike Feuersenger.;Dipti Pawaskar.;Iris Jacobs.;Ingo Pragst.;Mittie K Doyle.
来源: Lancet. 2022年399卷10328期945-955页
Hereditary angioedema is associated with dysregulation of the kallikrein-kinin system. Factor XII (FXII) is a key initiator of the kallikrein-kinin system, which produces bradykinin, a central mediator of angioedema. Garadacimab (CSL Behring) is a first-in-class, fully human, immunoglobulin G4 monoclonal antibody targeting activated FXII, intended to prevent attacks in patients with C1-esterase inhibitor-deficient hereditary angioedema (HAE-C1-INH). We aimed to investigate garadacimab as a treatment every 4 weeks for patients with HAE-C1-INH.
5051. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
The infection-fatality ratio (IFR) is a metric that quantifies the likelihood of an individual dying once infected with a pathogen. Understanding the determinants of IFR variation for COVID-19, the disease caused by the SARS-CoV-2 virus, has direct implications for mitigation efforts with respect to clinical practice, non-pharmaceutical interventions, and the prioritisation of risk groups for targeted vaccine delivery. The IFR is also a crucial parameter in COVID-19 dynamic transmission models, providing a way to convert a population's mortality rate into an estimate of infections.
5057. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
作者: Daniel R Feikin.;Melissa M Higdon.;Laith J Abu-Raddad.;Nick Andrews.;Rafael Araos.;Yair Goldberg.;Michelle J Groome.;Amit Huppert.;Katherine L O'Brien.;Peter G Smith.;Annelies Wilder-Smith.;Scott Zeger.;Maria Deloria Knoll.;Minal K Patel.
来源: Lancet. 2022年399卷10328期924-944页
Knowing whether COVID-19 vaccine effectiveness wanes is crucial for informing vaccine policy, such as the need for and timing of booster doses. We aimed to systematically review the evidence for the duration of protection of COVID-19 vaccines against various clinical outcomes, and to assess changes in the rates of breakthrough infection caused by the delta variant with increasing time since vaccination.
|